Introduction to Benlysta (Belimumab) Benlysta (belimumab), developed by GlaxoSmithKline (GSK), is a monoclonal antibody that targets and inhibits B-lymphocyte stimulator (BLyS), a protein critical to B-cell survival. Approved for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis, Benlysta represents a major advancement in autoimmune disease management by effectively...